Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial - Concepedia

Concepedia

Publication | Open Access

Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial

DOI Full Paper Access

52

Citations

21

References

2011

Year

Annette M. Lim, Danny Rischin, Richard Fisher, Hongbin Cao, Kathleen Kwok, Daniel D. Truong, Grant A. McArthur, Richard J. Young, Amato J. Giaccia, Lester Peters,

Clinical Cancer Research

Abstract

We found no evidence that high plasma OPN levels were associated with an adverse prognosis in HNSCC, or were predictive of benefit with hypoxia targeting therapy.

References

	Year	Citations
R: A Language and Environment for Statistical Computing R Core Team	2000	352.8K
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Marianne Nordsmark, Søren M. Bentzen, Volker Rudat, Radiotherapy and Oncology Radiation TherapyTumor OxygenationMedicinePrognostic ValueHead And Neck Cancer	2005	930
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02 Lester J. Peters, Brian O’Sullivan, J. Giralt, Journal of Clinical Oncology	2010	791
Prognostic Significance of p16 <sup>INK4A</sup> and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial Danny Rischin, Richard J. Young, Richard Fisher, Journal of Clinical Oncology	2010	738
Prognostic Significance of [<sup>18</sup>F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 Danny Rischin, Rodney J. Hicks, Richard Fisher, Journal of Clinical Oncology	2006	540
Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers Jens Overgaard, Michael R. Horsman Seminars in Radiation Oncology Radiation TherapyMedicineHypoxia (Medicine)Tissue OxygenationHypoxia-induced Radioresistance	1996	417
Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group Danny Rischin, Lester J. Peters, Brian O’Sullivan, Journal of Clinical Oncology	2010	370
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial Jens Overgaard, Jesper Grau Eriksen, Marianne Nordsmark, The Lancet Oncology Radiation TherapyDahanca 5MedicinePharmacologyHead And Neck Cancer	2005	271
Three small integrin‐binding ligand N‐linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases Neal S. Fedarko, Alka Jain, Abdullah Karadağ, The FASEB Journal SclerostinGlycobiologyMolecular BiologyLigand N‐linked GlycoproteinsTumor Biology	2004	222
Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack Neal S. Fedarko, Bert Fohr, Pamela Gehron Robey, Journal of Biological Chemistry	2000	215

Page 1